AKT inhibitor AZD5363 well tolerated, yielded partial response in patients with advanced solid tumors
The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR ...
Apr 8, 2013
0
0